High materiality7/10
Aclaris Therapeutics initiated with a Buy at Canaccord
Why it may matterVerify against the original reporting
Bullish setup driven by a Buy rating and upside target.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
ACRS received an analyst target update from Canaccord Genuity.
- Target: $10
- Posted price: $6.05
- Analyst firm: Canaccord Genuity
- Analyst: Edward Nash
- Direction: Buy (bullish)
Key facts
- 01
Target: $10
- 02
Posted price: $6.05
- 03
Analyst firm: Canaccord Genuity
- 04
Analyst: Edward Nash
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.